223 related articles for article (PubMed ID: 19405951)
1. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.
Sutherland KA; Rogers HL; Tosh D; Rogers MJ
Arthritis Res Ther; 2009; 11(2):R58. PubMed ID: 19405951
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Frith JC; Rogers MJ
J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
[TBL] [Abstract][Full Text] [Related]
4. Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors.
Tai TW; Su FC; Chen CY; Jou IM; Lin CF
Bone; 2014 Oct; 67():166-74. PubMed ID: 25016096
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
6. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
7. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
Benford HL; McGowan NW; Helfrich MH; Nuttall ME; Rogers MJ
Bone; 2001 May; 28(5):465-73. PubMed ID: 11344045
[TBL] [Abstract][Full Text] [Related]
8. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
9. A medium-chain fatty acid, capric acid, inhibits RANKL-induced osteoclast differentiation via the suppression of NF-κB signaling and blocks cytoskeletal organization and survival in mature osteoclasts.
Kim HJ; Yoon HJ; Kim SY; Yoon YR
Mol Cells; 2014 Aug; 37(8):598-604. PubMed ID: 25134536
[TBL] [Abstract][Full Text] [Related]
10. Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation.
Tsubaki M; Komai M; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
J Biomed Sci; 2014 Feb; 21(1):10. PubMed ID: 24490900
[TBL] [Abstract][Full Text] [Related]
11. Macrophage colony-stimulating factor promotes the survival of osteoclast precursors by up-regulating Bcl-X(L).
Woo KM; Kim HM; Ko JS
Exp Mol Med; 2002 Nov; 34(5):340-6. PubMed ID: 12526097
[TBL] [Abstract][Full Text] [Related]
12. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
13. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
[TBL] [Abstract][Full Text] [Related]
15. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
[TBL] [Abstract][Full Text] [Related]
16. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
[TBL] [Abstract][Full Text] [Related]
17. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
19. Quercetin triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts and inhibits bone resorption in RAW264.7 cells.
Guo C; Hou GQ; Li XD; Xia X; Liu DX; Huang DY; Du SX
Cell Physiol Biochem; 2012; 30(1):123-36. PubMed ID: 22759961
[TBL] [Abstract][Full Text] [Related]
20. Bone Remodeling and the Role of TRAF3 in Osteoclastic Bone Resorption.
Boyce BF; Li J; Xing L; Yao Z
Front Immunol; 2018; 9():2263. PubMed ID: 30323820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
